Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill (Lung Cancer Medicare Access to Precise Testing Act) amends the Social Security Act to require that Medicare cover “lung cancer biomarker testing” (defined as tests performed on or after January 1, 2027, on tissue, blood, or bodily fluids to identify one or more specific biomarkers). It adds lung cancer biomarker testing to the list of covered items and requires that Medicare pay 100 percent of the reasonable charges for such testing.
Extent of federal spending and whether a 100% payment mandate will raise Medicare costs (centrist and conservative focus on fiscal impacts; liberal focuses more on access).
Relative to its intended legislative type, this bill is a straightforward statutory amendment that adds a new Medicare-covered service (lung cancer biomarker testing), defines the term, sets an effective date, and prescribes payment at 100% of reasonable charges.
This bill (Lung Cancer Medicare Access to Precise Testing Act) amends the Social Security Act to require that Medicare cover “lung cancer biomarker testing” (defined as tests performed on or after January 1, 2027, on tissue, blood, or bodily fluids to identify one or more specific biomarkers).
It adds lung cancer biomarker testing to the list of covered items and requires that Medicare pay 100 percent of the reasonable charges for such testing.
The bill does not specify particular biomarkers or testing platforms beyond the general definition, nor does add detailed utilization or evidentiary criteria in the text provided.
On content alone the bill is a focused, administrable change to Medicare coverage that could attract support from patient advocates, clinicians, and industry stakeholders; however, the explicit 100% payment requirement and resulting likely increase in Medicare spending introduce fiscal objections and reduce the bill's chance relative to purely technical or budget-neutral fixes. The lack of compromise features (sunset/phase-in/offsets) is a modest headwind. Overall, content suggests a moderate chance of becoming law contingent on cost discussion and potential amendments.
Relative to its intended legislative type, this bill is a straightforward statutory amendment that adds a new Medicare-covered service (lung cancer biomarker testing), defines the term, sets an effective date, and prescribes payment at 100% of reasonable charges. It integrates directly into the Social Security Act but leaves operational, clinical, and fiscal implementation details to administrative processes.
Extent of federal spending and whether a 100% payment mandate will raise Medicare costs (centrist and conservative focus on fiscal impacts; liberal focuses more on access).
These are examples from the analysis, not a ranked list of the most-affected groups.
Extent of federal spending and whether a 100% payment mandate will raise Medicare costs (centrist and conservative focus on fiscal impacts; liberal focuses more on access).
A mainstream liberal would likely view this bill positively as expanding access to precision diagnostics for people with lung cancer on Medicare, reducing financial barriers to tests that can inform treatment decisions.
They would see the 100 percent payment provision as a way to eliminate out-of-pocket costs for beneficiaries and to promote equity in cancer care, especially for low-income and rural seniors.
They may also want safeguards to ensure tests are clinically appropriate and affordable, and push for similar coverage for other cancers.
A centrist would generally view the bill as a targeted, pragmatic expansion of Medicare coverage that could improve patient care but would want more information on fiscal impacts and implementation details.
They would appreciate the focus on a specific clinical need (lung cancer biomarkers) and the potential downstream efficiencies from better-targeted treatments, but would also be cautious about open-ended cost exposure from a 100 percent payment rule.
Centrists would likely press for guardrails such as evidence standards, utilization monitoring, and cost controls to ensure the policy is fiscally responsible and delivers value.
A mainstream conservative would be skeptical of the bill’s expansion of federally mandated coverage and the requirement that Medicare pay 100 percent of reasonable charges.
They would raise concerns about increased federal spending, potential for higher Medicare payments to labs, and expanded federal intervention in medical decision-making and pricing.
If persuaded, some conservatives might accept targeted coverage for diagnostics that demonstrably lower overall costs of care, but many would prefer tighter evidence and cost controls before supporting a new entitlement-style coverage requirement.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is a focused, administrable change to Medicare coverage that could attract support from patient advocates, clinicians, and industry stakeholders; however, the explicit 100% payment requirement and resulting likely increase in Medicare spending introduce fiscal objections and reduce the bill's chance relative to purely technical or budget-neutral fixes. The lack of compromise features (sunset/phase-in/offsets) is a modest headwind. Overall, content suggests a moderate chance of becoming law contingent on cost discussion and potential amendments.
The bill has not accumulated any surfaced votes yet.
Extent of federal spending and whether a 100% payment mandate will raise Medicare costs (centrist and conservative focus on fiscal impacts;…
On content alone the bill is a focused, administrable change to Medicare coverage that could attract support from patient advocates, clinic…
Relative to its intended legislative type, this bill is a straightforward statutory amendment that adds a new Medicare-covered service (lung cancer biomarker testing), defines the term, sets an effective date, and presc…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.